Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Sanofi ( (SNY) ) is now available.
Sanofi has released its condensed half-year consolidated financial statements for the six months ending June 30, 2025, along with information on its financial results for the first half and third quarter of 2025. The report highlights a decrease in total assets from December 2024 to June 2025, indicating potential challenges in asset management or strategic adjustments. This financial disclosure provides stakeholders with insights into Sanofi’s financial health and operational performance during the first half of the year.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and solid profitability support the score, despite some challenges in cash flow and revenue growth. Technical analysis indicates a stable market position, contributing to a positive outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a multinational pharmaceutical company based in Paris, France, specializing in the development, manufacturing, and marketing of pharmaceutical products. The company focuses on a wide range of therapeutic areas including diabetes, oncology, and vaccines, positioning itself as a leader in the global healthcare industry.
Average Trading Volume: 3,238,473
Technical Sentiment Signal: Strong Buy
Current Market Cap: $126B
See more insights into SNY stock on TipRanks’ Stock Analysis page.